Toggle Main Menu Toggle Search

Open Access padlockePrints

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer

Lookup NU author(s): Professor Alan Boddy, Huw ThomasORCiD, Lynsey Robson, Professor Alan Calvert


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


The aim of this phase I study was to determine the maximum tolerated dose of a 3-h infusion of paclitaxel, combined with carboplatin at a fixed AUC of 7 mg ml-1 min every 4 weeks for up to six cycles and to evaluate any possible pharmacokinetic interaction. Twelve chemonaive patients with ovarian cancer were treated with paclitaxel followed by a 30-min infusion of carboplatin. Paclitaxel dose was escalated from 150 mg m-2 to 225 mg m-2 in cohorts of three patients. Carboplatin dose was based on renal function, Pharmacokinetic studies were performed in nine patients (at least two at each dose level). A total of 66 courses were evaluable for assessment. Grade 3 or 4 neutropenia was seen in 70% of the courses, however hospitalization was not required. Grade 3 or 4 thrombocytopenia occurred in 24% of the courses. Alopecia, myalgia and peripheral neuropathy were common but rarely severe. The pharmacokinetics of paclitaxel was non-linear and did not appear to be influenced by co-administration of carboplatin. The AUC of carboplatin was 7.0 ± 1.4 mg ml-1 min, indicating that there was no pharmacokinetic interaction. The combination of carboplatin and paclitaxel may be administered as first-line treatment for advanced ovarian cancer. Although myelosuppression is the dose-limiting toxicity of the component drugs, the severity of thrombocytopenia was less than anticipated. The results of this study, with only a small number of patients, need to be confirmed in future investigations.

Publication metadata

Author(s): Siddiqui N, Boddy AV, Thomas HD, Bailey N, Robson L, Lind M, Calvert AH

Publication type: Article

Publication status: Published

Journal: British Journal of Cancer

Year: 1997

Volume: 75

Issue: 2

Pages: 287-294

Print publication date: 01/01/1997

ISSN (print): 0007-0920

ISSN (electronic):


PubMed id: 9010040